TP53 Mutations in Mantle Cell Lymphoma: From Backup to Game Changer

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Mantle Cell Lymphoma (MCL) is an aggressive non-Hodgkin lymphoma (NHL).
• TP53 mutations are significant prognostic markers in MCL, linked to treatment resistance and reduced survival.
• Current clinical practice rarely includes routine TP53 mutation testing at diagnosis.

Purpose of the Study:

• To review advances in integrated-omics for assessing TP53 status in MCL.
• To highlight the gap between research findings on TP53 mutations and clinical implementation.
• To emphasize the need for standardized genomic techniques for risk-adapted therapy.

Main Methods:

• Review of integrated-omics approaches for TP53 mutation assessment.
• Analysis of the prognostic impact of TP53 mutations in MCL.
• Examination of barriers to routine TP53 testing (NGS costs, IHC reliability).

Main Results:

• TP53 mutations consistently predict chemoimmunotherapy resistance and poorer outcomes in MCL.
• Despite strong evidence, routine TP53 testing is uncommon due to practical challenges.
• Clinical trials show promise for targeted therapies in TP53-mutated MCL patients.

Conclusions:

• Early molecular risk assessment, particularly TP53 mutation status, is crucial for guiding MCL treatment.
• Standardized and accessible genomic testing is essential for personalized therapeutic approaches.
• TP53 mutations are a game-changer in MCL prognosis and management, necessitating a paradigm shift towards risk-adapted therapy.